Literature DB >> 17661153

Brain tau expression and correlation with the H1/H1 tau genotype in frontotemporal lobar degeneration patients.

A Lladó1, M Ezquerra, C Gaig, R Sánchez-Valle, E Tolosa, J L Molinuevo.   

Abstract

Alterations in tau mRNA splicing and association with H1/H1 tau genotype have been described in some sporadic tauopathies. We evaluated the 4R/3R tau mRNA ratio in 18 patients with frontotemporal lobar degeneration (FTLD), and the effect of the H1/H1 genotype on this ratio. The 4R/3R mRNA ratio in frontal cortex was similar in FTLD patients and controls. The H1/H1 genotype carriers showed a significant increase in 4R/3R mRNA ratio, suggesting that this genotype could modulate the tau mRNA splicing.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17661153     DOI： 10.1007/s00702-007-0786-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  18 in total

1.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

2.  High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy.

Authors:  Rosa Rademakers; Stacey Melquist; Marc Cruts; Jessie Theuns; Jurgen Del-Favero; Parvoneh Poorkaj; Matt Baker; Kristel Sleegers; Richard Crook; Tim De Pooter; Samira Bel Kacem; Jennifer Adamson; Dirk Van den Bossche; Marleen Van den Broeck; Jennifer Gass; Ellen Corsmit; Peter De Rijk; Natalie Thomas; Sebastiaan Engelborghs; Michael Heckman; Irene Litvan; Julia Crook; Peter P De Deyn; Dennis Dickson; Gerard D Schellenberg; Christine Van Broeckhoven; Michael L Hutton
Journal:  Hum Mol Genet       Date:  2005-09-29       Impact factor: 6.150

3.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy.

Authors:  M Baker; I Litvan; H Houlden; J Adamson; D Dickson; J Perez-Tur; J Hardy; T Lynch; E Bigio; M Hutton
Journal:  Hum Mol Genet       Date:  1999-04       Impact factor: 6.150

4.  Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease.

Authors:  C B Chambers; J M Lee; J C Troncoso; S Reich; N A Muma
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

5.  Novel tau polymorphisms, tau haplotypes, and splicing in familial and sporadic frontotemporal dementia.

Authors:  Maria-Jesús Sobrido; Bruce L Miller; Necat Havlioglu; Victoria Zhukareva; Zhihong Jiang; Ziad S Nasreddine; Virginia M-Y Lee; Tiffany W Chow; Kirk C Wilhelmsen; Jeffrey L Cummings; Jane Y Wu; Daniel H Geschwind
Journal:  Arch Neurol       Date:  2003-05

6.  Association between the extended tau haplotype and frontotemporal dementia.

Authors:  Patrice Verpillat; Agnès Camuzat; Didier Hannequin; Catherine Thomas-Anterion; Michèle Puel; Serge Belliard; Bruno Dubois; Mira Didic; Bernard-François Michel; Lucette Lacomblez; Olivier Moreaud; François Sellal; Véronique Golfier; Dominique Campion; Françoise Clerget-Darpoux; Alexis Brice
Journal:  Arch Neurol       Date:  2002-06

7.  alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease.

Authors:  Nigel J Cairns; Victoria Zhukareva; Kunihiro Uryu; Bin Zhang; Eileen Bigio; Ian R A Mackenzie; Marla Gearing; Charles Duyckaerts; Hideaki Yokoo; Yoichi Nakazato; Evelyn Jaros; Robert H Perry; Virginia M-Y Lee; John Q Trojanowski
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

8.  Quantitative analysis of tau isoform transcripts in sporadic tauopathies.

Authors:  J W Connell; T Rodriguez-Martin; G M Gibb; N M Kahn; A J Grierson; D P Hanger; T Revesz; P L Lantos; B H Anderton; J-M Gallo
Journal:  Brain Res Mol Brain Res       Date:  2005-03-29

9.  Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration.

Authors:  A M Pittman; A J Myers; P Abou-Sleiman; H C Fung; M Kaleem; L Marlowe; J Duckworth; D Leung; D Williams; L Kilford; N Thomas; C M Morris; D Dickson; N W Wood; J Hardy; A J Lees; R de Silva
Journal:  J Med Genet       Date:  2005-03-25       Impact factor: 6.318

10.  The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts.

Authors:  Amanda J Myers; Alan M Pittman; Alice S Zhao; Kristen Rohrer; Mona Kaleem; Lauren Marlowe; Andrew Lees; Doris Leung; Ian G McKeith; Robert H Perry; Chris M Morris; John Q Trojanowski; Christopher Clark; Jason Karlawish; Steve Arnold; Mark S Forman; Vivianna Van Deerlin; Rohan de Silva; John Hardy
Journal:  Neurobiol Dis       Date:  2006-12-15       Impact factor: 5.996
View more
  3 in total

1.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

2.  Tau levels do not influence human ALS or motor neuron degeneration in the SOD1G93A mouse.

Authors:  I Taes; A Goris; R Lemmens; M A van Es; L H van den Berg; A Chio; B J Traynor; A Birve; P Andersen; A Slowik; B Tomik; R H Brown; C E Shaw; A Al-Chalabi; S Boonen; L Van Den Bosch; B Dubois; P Van Damme; W Robberecht
Journal:  Neurology       Date:  2010-05-25       Impact factor: 9.910

Review 3.  The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades.

Authors:  José Luis Molinuevo; Carolina Minguillon; Lorena Rami; Juan Domingo Gispert
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.